In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors

Gerhard Bauer, Mo A. Dao, Scott S. Case, Todd Meyerrose, Louisa Wirthlin, Ping Zhou, Xiuli Wang, Phillip Herrbrich, Jesusa Arevalo, Susie Csik, Dianne C. Skelton, Jon Walker, Karen Pepper, Donald B. Kohn, Jan Nolta

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Serious adverse events in some human gene therapy clinical trials have raised safety concerns when retroviral or lentiviral vectors are used for gene transfer. We evaluated the potential for generating replication-competent retrovirus (RCR) and assessed the risk of occurrence of adverse events in an in vivo system. Human hematopoietic stem and progenitor cells (HSCs) and mesenchymal stem cells (MSCs) transduced with two different Moloney murine leukemia virus (MoMuLV)-based vectors were cotransplanted into a total of 481 immune-deficient mice (that are unable to reject cells that become transformed), and the animals were monitored for 18 months. Animals with any signs of illness were immediately killed, autopsied, and subjected to a range of biosafety studies. There was no detectable evidence of insertional mutagenesis leading to human leukemias or solid tumors in the 18 months during which the animals were studied. In 117 serum samples analyzed by vector rescue assay there was no detectable RCR. An additional 149 mice received HSCs transduced with lentiviral vectors, and were followed for 2-6 months. No vector-associated adverse events were observed, and none of the mice had detectable human immunodeficiency virus (HIV) p24 antigen in their sera. Our in vivo system, therefore, helps to provide an assessment of the risks involved when retroviral or lentiviral vectors are considered for use in clinical gene therapy applications.

Original languageEnglish (US)
Pages (from-to)1308-1315
Number of pages8
JournalMolecular Therapy
Volume16
Issue number7
DOIs
StatePublished - Jul 2008

Fingerprint

Hematopoietic Stem Cells
Retroviridae
Genetic Therapy
Moloney murine leukemia virus
Insertional Mutagenesis
Serum
Mesenchymal Stromal Cells
Leukemia
Clinical Trials
HIV
Safety
Antigens
Genes
Neoplasms

ASJC Scopus subject areas

  • Molecular Biology

Cite this

In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors. / Bauer, Gerhard; Dao, Mo A.; Case, Scott S.; Meyerrose, Todd; Wirthlin, Louisa; Zhou, Ping; Wang, Xiuli; Herrbrich, Phillip; Arevalo, Jesusa; Csik, Susie; Skelton, Dianne C.; Walker, Jon; Pepper, Karen; Kohn, Donald B.; Nolta, Jan.

In: Molecular Therapy, Vol. 16, No. 7, 07.2008, p. 1308-1315.

Research output: Contribution to journalArticle

Bauer, G, Dao, MA, Case, SS, Meyerrose, T, Wirthlin, L, Zhou, P, Wang, X, Herrbrich, P, Arevalo, J, Csik, S, Skelton, DC, Walker, J, Pepper, K, Kohn, DB & Nolta, J 2008, 'In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors', Molecular Therapy, vol. 16, no. 7, pp. 1308-1315. https://doi.org/10.1038/mt.2008.93
Bauer, Gerhard ; Dao, Mo A. ; Case, Scott S. ; Meyerrose, Todd ; Wirthlin, Louisa ; Zhou, Ping ; Wang, Xiuli ; Herrbrich, Phillip ; Arevalo, Jesusa ; Csik, Susie ; Skelton, Dianne C. ; Walker, Jon ; Pepper, Karen ; Kohn, Donald B. ; Nolta, Jan. / In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors. In: Molecular Therapy. 2008 ; Vol. 16, No. 7. pp. 1308-1315.
@article{1e1cef7e95c047a6899307db10511a53,
title = "In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors",
abstract = "Serious adverse events in some human gene therapy clinical trials have raised safety concerns when retroviral or lentiviral vectors are used for gene transfer. We evaluated the potential for generating replication-competent retrovirus (RCR) and assessed the risk of occurrence of adverse events in an in vivo system. Human hematopoietic stem and progenitor cells (HSCs) and mesenchymal stem cells (MSCs) transduced with two different Moloney murine leukemia virus (MoMuLV)-based vectors were cotransplanted into a total of 481 immune-deficient mice (that are unable to reject cells that become transformed), and the animals were monitored for 18 months. Animals with any signs of illness were immediately killed, autopsied, and subjected to a range of biosafety studies. There was no detectable evidence of insertional mutagenesis leading to human leukemias or solid tumors in the 18 months during which the animals were studied. In 117 serum samples analyzed by vector rescue assay there was no detectable RCR. An additional 149 mice received HSCs transduced with lentiviral vectors, and were followed for 2-6 months. No vector-associated adverse events were observed, and none of the mice had detectable human immunodeficiency virus (HIV) p24 antigen in their sera. Our in vivo system, therefore, helps to provide an assessment of the risks involved when retroviral or lentiviral vectors are considered for use in clinical gene therapy applications.",
author = "Gerhard Bauer and Dao, {Mo A.} and Case, {Scott S.} and Todd Meyerrose and Louisa Wirthlin and Ping Zhou and Xiuli Wang and Phillip Herrbrich and Jesusa Arevalo and Susie Csik and Skelton, {Dianne C.} and Jon Walker and Karen Pepper and Kohn, {Donald B.} and Jan Nolta",
year = "2008",
month = "7",
doi = "10.1038/mt.2008.93",
language = "English (US)",
volume = "16",
pages = "1308--1315",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors

AU - Bauer, Gerhard

AU - Dao, Mo A.

AU - Case, Scott S.

AU - Meyerrose, Todd

AU - Wirthlin, Louisa

AU - Zhou, Ping

AU - Wang, Xiuli

AU - Herrbrich, Phillip

AU - Arevalo, Jesusa

AU - Csik, Susie

AU - Skelton, Dianne C.

AU - Walker, Jon

AU - Pepper, Karen

AU - Kohn, Donald B.

AU - Nolta, Jan

PY - 2008/7

Y1 - 2008/7

N2 - Serious adverse events in some human gene therapy clinical trials have raised safety concerns when retroviral or lentiviral vectors are used for gene transfer. We evaluated the potential for generating replication-competent retrovirus (RCR) and assessed the risk of occurrence of adverse events in an in vivo system. Human hematopoietic stem and progenitor cells (HSCs) and mesenchymal stem cells (MSCs) transduced with two different Moloney murine leukemia virus (MoMuLV)-based vectors were cotransplanted into a total of 481 immune-deficient mice (that are unable to reject cells that become transformed), and the animals were monitored for 18 months. Animals with any signs of illness were immediately killed, autopsied, and subjected to a range of biosafety studies. There was no detectable evidence of insertional mutagenesis leading to human leukemias or solid tumors in the 18 months during which the animals were studied. In 117 serum samples analyzed by vector rescue assay there was no detectable RCR. An additional 149 mice received HSCs transduced with lentiviral vectors, and were followed for 2-6 months. No vector-associated adverse events were observed, and none of the mice had detectable human immunodeficiency virus (HIV) p24 antigen in their sera. Our in vivo system, therefore, helps to provide an assessment of the risks involved when retroviral or lentiviral vectors are considered for use in clinical gene therapy applications.

AB - Serious adverse events in some human gene therapy clinical trials have raised safety concerns when retroviral or lentiviral vectors are used for gene transfer. We evaluated the potential for generating replication-competent retrovirus (RCR) and assessed the risk of occurrence of adverse events in an in vivo system. Human hematopoietic stem and progenitor cells (HSCs) and mesenchymal stem cells (MSCs) transduced with two different Moloney murine leukemia virus (MoMuLV)-based vectors were cotransplanted into a total of 481 immune-deficient mice (that are unable to reject cells that become transformed), and the animals were monitored for 18 months. Animals with any signs of illness were immediately killed, autopsied, and subjected to a range of biosafety studies. There was no detectable evidence of insertional mutagenesis leading to human leukemias or solid tumors in the 18 months during which the animals were studied. In 117 serum samples analyzed by vector rescue assay there was no detectable RCR. An additional 149 mice received HSCs transduced with lentiviral vectors, and were followed for 2-6 months. No vector-associated adverse events were observed, and none of the mice had detectable human immunodeficiency virus (HIV) p24 antigen in their sera. Our in vivo system, therefore, helps to provide an assessment of the risks involved when retroviral or lentiviral vectors are considered for use in clinical gene therapy applications.

UR - http://www.scopus.com/inward/record.url?scp=45749105103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749105103&partnerID=8YFLogxK

U2 - 10.1038/mt.2008.93

DO - 10.1038/mt.2008.93

M3 - Article

C2 - 18461052

AN - SCOPUS:45749105103

VL - 16

SP - 1308

EP - 1315

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 7

ER -